Dr Steve Webb is an ICU physician and a Professor of Critical Care Research at Monash University. He was a founding director and former Chair of the Australian Clinical Trials Alliance, a past-Chair of the ANZICS Clinical Trials Group and a Foundation Fellow of the Australian Academy of Health and Medical Sciences.

He was a founding investigator and inaugural chair of the REMAP-CAP International Trials Steering Committee and led the platform through the pandemic reporting the treatment effect of multiple different interventions for patients with life-threatening COVID-19 infection.

He has been an investigator on trials with an accumulated sample size of more than 65,000 patients, is a named investigator on more than $160 M of competitive research funding and has published more than 250 manuscripts, including multiple manuscripts in NEJM and JAMA, that have been cited more than 60,000 times.

Scott Berry is President and a Senior Statistical Scientist at Berry Consultants, LLC.  He earned his PhD in statistics from Carnegie Mellon University and was an Assistant Professor at Texas A&M University before co-founding Berry Consultants in 2000. He is adjunct faculty in the Department of Biostatistics at the University of Kansas Medical Center. Dr. Berry was elected as a Fellow of the American Statistical Association in 2013.

Since 2000, he has been involved in the design of hundreds of Bayesian adaptive clinical trials of pharmaceuticals and medical devices and has become an opinion leader in the field of Bayesian adaptive clinical trials. Some of these trials have been groundbreaking trial designs, setting new standards for innovation and flexibility in trial design. These include the statistical analysis of the first fully Bayesian approval by CDER of the United States FDA (Pravastatin-Aspirin combination), a Bayesian adaptive phase 2 design leading to Lecanemab’s phase 3 trial in sporadic Alzheimer’s disease and eventual FDA approval, and an adaptive phase II/III seamless trial for Dulaglutide (Trulicity) leading to FDA approval in September 2014. He has been involved in the design of multiple adaptive platforms trials, including the global platform trials (REMAP-CAP and ACTIV-4a) in COVID-19.

Twitter:  @BerryConsultant

Tim Walsh is Professor of Critical Care at the University of Edinburgh and Honorary Consultant in Critical Care at Edinburgh Royal Infirmary. He is also Director Innovation for NHS Lothian, and Health Innovation South East Scotland. He is Head of the Academic Dept of Anaesthesia, Critical Care, and Pain Medicine in the University of Edinburgh, and Co-director of Acute Care Edinburgh a multidisciplinary research grouping in the University of Edinburgh Usher Institute.

Tim leads a multidisciplinary clinical research group with interests including transfusion medicine, sedation in the critically ill, recovery from critical illness and the epidemiology and prevention of ICU acquired infection. He has a particular interest in large pragmatic clinical trials, complex health intervention trials, and the evaluation of novel diagnostics and technologies in acute care. He is a past Chairman of the NIHR UK Critical Care Research Network and UK Critical Care Research Group, and has led many large trials and served on numerous Trial Steering and Data Monitoring Committees.

Twitter:  @Ed_TimWalsh

Chris Weir is Professor of Medical Statistics & Clinical Trials in the University of Edinburgh’s Usher Institute and is based within the Edinburgh Clinical Trials Unit (ECTU). He holds a BSc in Statistics, an MSc in Public Health and Health Services Research and a PhD exploring the development of an expert system to support clinical decision-making in acute stroke. He is the statistician co-investigator on several ongoing clinical trials within the ECTU portfolio and has a parallel interest in clinical trials methodology research. Two key methodology themes are adaptive clinical trial designs (and more generally, complex and innovative trial design); and the development and application of methods to evaluate putative clinical trial surrogate outcome measures. As a member of the Commission on Human Medicines, he contributes to the oversight of UK regulatory decisions on licensing applications.

Alistair is the Chair of Critical Care Medicine in University College Dublin (UCD), and the Director of the Irish Critical Care - Clinical Trials Network (ICC-CTN). He is the Dept Director of the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia. Alistair works clinically in St. Vincent’s University Hospital in Dublin and is an honorary Intensivist in the Alfred Hospital in Melbourne. He has been awarded over 70 million euros in research funding and published numerous articles in the world’s highest impact journals, including first author publications in the NEJM, Lancet and JAMA. Apart from having multiple jobs Alistair also has 4 kids under 16 years of age. He obviously therefore has no hobbies, no sporting interests but he lives in hope of this improving :)

Dr. Madiha, MD, FFARCS is a Professor and Chair, of the Department of Critical Care Medicine, at Ziauddin University, Karachi, and Visiting Faculty at Aga Khan University, Karachi, Pakistan. She is an Honorary Physician, at Mahidol Oxford Research Unit, Bangkok, Thailand, and a Member of the Board of Directors of the International Severe Acute Respiratory & emerging Infections Consortium (ISARIC).

Madiha serves as Secretary, of the Faculty of CCM, College of Physicians & Surgeons Pakistan, and CEO of the South-East Asian Research & Education in Critical care Health (SEARCH), founded to promote research in critical care in Pakistan. She was President of the Pakistan Society of Critical Care Medicine from 2015–2019, leading the Pakistan Registry of Intensive Care (PRICE) which is operational across the country.

Madiha acted as Principal Investigator for Pakistan for the REMAP-CAP Trial, and for operationalizing the WHO/ISARIC CCP during the COVID-19 pandemic in intensive care units across the country. She served as a GDC member for WHO guidance and guidelines on clinical management and therapeutics for COVID-19 (WHO, 2020–2021), and the new WHO Living guideline: drugs to prevent COVID-19 (WHO, 2021).

Twitter:  @PRICE_critcare

Deborah Cook is a Distinguished Professor of Medicine and Academic Chair of Critical Care in the Departments of Medicine, Health Research Methods, Evidence, and Impact at McMaster University. As co-founder and past chair of the Canadian Critical Care Trials Group (CCCTG), she has championed clinical research in collaboration with bedside colleagues, early and established scientists, patients and families.

While practising in the ICU at St. Joseph’s Healthcare Hamilton, Dr. Cook’s studies on advanced life support, preventing ICU complications, research ethics and end-of-life care have informed practice and policy. It has been her privilege to help lead the REVISE Trial with hundreds of energetic friends and colleagues from the CCCTG, the ANZICS-CTG and around the world.

Once he appreciated that being both scared of short pitched bowling and having a weakness against the swinging ball outside off-stump were major impediments to his dream of batting first drop for the Australian cricket team, Adam transitioned his career aspirations to medicine.

He currently pays the mortgage with employment as Staff Specialist, Head of Intensive Care Unit Research, and Deputy Director Intensive Care Unit at The Royal Melbourne Hospital. His academic appointments include Professorial Fellow in Intensive Care and Deputy Director of the Department of Critical Care Medicine at the University of Melbourne. From an earlier age, Adam developed a passion for frozen milk-based foods that stimulate sweet taste receptors. He continues to enjoy
following this passion whenever possible.

Twitter:  @MelbourneICU

Dr Turgeon is Professor and Director of Research in the Department of Anesthesiology and Critical Care Medicine, Université Laval, Québec City, Québec, Canada. He is a scientist at the CHU de Québec-Université Laval Research Center and practices critical care medicine at l’Hôpital de l’Enfant-Jésus of the CHU de Québec-Université Laval. He leads extensive collaborative research programs in neurocritical care medicine including BRAINapt, a newly funded international platform trial in critically ill patients with traumatic brain injury (TBI).

In the last years, he led the HEMOTION trial, a multicenter international trial on red blood cell transfusion thresholds in TBI. His research is funded by the Canadian Institutes of Health Research (CIHR). Dr Turgeon is the chairholder of the Canada Research Chair in Critical Care Neurology and Trauma.

Twitter:  @AlexisTurgeon_

François Lauzier is an Associate Professor in the Department of Medicine and Anesthesiology & Critical Care at l’Université Laval and a scientist at the Centre de recherche du CHU de Québec-Université Laval. He obtained his medical degree and completed a residency in internal medicine and a master’s degree in clinical epidemiology at l’Université de Sherbrooke. He then completed his critical care medicine training and clinical research fellowship at McMaster University. He has been a Fonds de la recherche du Québec-Santé (FRQS) career award recipient over the last decade and his research work are mainly supported by the Canadian Institutes of Health Research (CIHR).

Dr. Lauzier is the co-lead of the HEMOTION trial, the largest transfusion threshold trial ever conducted in patients with moderate and severe traumatic brain injury (TBI). He also currently co-leads BRAINapt, the first international platform trial in critically ill patients with moderate and severe TBI, recently funded by the CIHR.

Twitter: @LauzierFrancoi1

Martina Baiardo Redaelli, MD, is an ICU physician at San Raffaele University Hospital in Milan, Italy.

With an early and strong clinical and research interest in intensive care, she is co-author of more than 50 publications and she served as reviewer of numerous journals. She is co-investigator of several national and international randomized controlled trials and local principal investigator for intensive care studies.
Her clinical experience was enhanced by one year working as in charge of an ICU in Afghanistan, where she started one of the first residency programs in Anesthesia of the country. She is currently involved in the training of Anesthesia and Intensive Care residents and medical students from Vita-Salute San Raffaele University in Milan, Italy and she was co-supervisor of several graduation and residency thesis.

For the #PROTECTIONtrial @BaiardoMartina was part of the research team since the beginning of the study, taking part to the project from the ideation of the protocol to its final writing.

Twitter:  @BaiardoMartina

Prof Giovanni Landoni, MD, is currently Full Professor and Residency Program Director of Anesthesia and Intensive Care Medicine at Vita-Salute San Raffaele University, Milan. He’s also Director of the Center for Intensive Care and Anesthesiology of San Raffaele Hospital in Milan. In the period 2006-2024 he participated to ideation, writing and implementation of 30 grants that got funding from national and international donors.

He served as reviewer for over 50 journals (NEJM, JAMA, and The Lancet among others) and for foreign grant agencies, and he is member of the Editorial Board of several international journals.

His strong clinical and research interests in intensive care and anesthesia resulted in more than 700 scientific publications in indexed journals, cited >20,000 times, HI=75 on Scopus, including randomized trials on NEJM, Lancet, and JAMA, and over 100 invitations in international congresses. He participated to 64 published randomized controlled trials. Prof Landoni was Chief Investigator in successfully completed multicenter randomized clinical trials that randomized > 10,000 critically ill or perioperative patients over the last 10 years. He has filed applications for 6 patents in the field.

Twitter:  @giovannilandoni

Dr. Kevin Gibbs is an associate professor of medicine in the section of pulmonary, critical care, allergy and immunologic disease at Wake Forest School of Medicine in Winston-Salem, North Carolina, USA. He is the director of medical ICU clinical trials. His research focuses on the conduct of both conventional and pragmatic clinical trials in the acute care setting, with an emphasis on invasive mechanical ventilation and emergency tracheal intubation. He also conducts translational research on the intersection of metabolism and inflammation in critical illness.

Twitter:  @KevinGibbsMD

Dr. Michelle Kho is an Associate Professor in the School of Rehabilitation Science at McMaster University in Hamilton, Canada. As a clinician-scientist, she is a member of the Physiotherapy Department and cares for patients in the intensive care unit at St. Joseph’s Healthcare Hamilton.

In collaboration with the Canadian Critical Care Trials Group, Dr. Kho led CYCLE, the largest randomized clinical trial of early in-bed cycling in mechanically ventilated patients to improve patient outcomes (www.icucycle.com). She held a Tier II Canada Research Chair in Critical Care Rehabilitation and Knowledge Translation from the Canadian Institutes of Health Research (CIHR) for this research. Dr. Kho is also co-leading REVIVe, a 900-patient national study of frailty, rehabilitation, and outcomes in critically ill adult and pediatric survivors of COVID-19 and acute respiratory infection. Her research is funded by agencies including the CIHR and the Canadian Foundation for Innovation.

Twitter:  @khome

Dr. Heather O’Grady completed her PhD in Rehabilitation Science at McMaster University in Hamilton, Canada. Her research interests are focused on rehabilitation, knowledge translation and patient-engaged research in the context of critical illness. Dr. O’Grady has been involved with the CYCLE program of research since 2017 and is currently working as research staff at the CYCLE RCT methods centre.

Twitter:  @ogradyhk

Simon Finfer is Professorial Fellow in the Critical Care Division at The George Institute for Global Health in Sydney, Adjunct Professor, University of New South Wales and Professor of Critical Care, School of Public Health, Imperial College London.

He leads the Sepsis Research Program at The George Institute which is focussed on the design and conduct of robust high quality RCTs that will reduce death and disability due to sepsis in Australia and around the world.

Simon has obtained over $50M in research funding and authored or co-authored over 250 peer reviewed papers with 20% of those in the highest-ranking medical journals. He served as a guest editor for the New England Journal of Medicine from 2012 to 2014 and is currently an editor of the Oxford Textbook of Critical Care and the Critical Care Section Editor of the Oxford Textbook of Medicine.

Simon was a founding member and is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group, past chair of the International Sepsis Forum, and past Vice President of the Global Sepsis Alliance. He is Director of the Australian Sepsis Network and Asia Pacific Sepsis Alliance.

A Fellow of the Australian Academy of Health and Medical Sciences, Simon was appointed an Officer (AO) in the Order of Australia in the Queen’s Birthday Honours List 2020 for “distinguished service to intensive care medicine, to medical research and education, and to global health institutes”

Jan Gunst, M.D., Ph.D., is board-certified specialist in anesthesiology and intensive care medicine. He is Associate Professor of Medicine at the Laboratory of Intensive Care Medicine at KU Leuven, Leuven, Belgium, and staff physician-intensivist in the Clinical Department of Intensive Care Medicine at the University Hospitals Leuven. His research focuses on endocrinology, metabolism, and nutrition of critical illness, combining clinical and translational studies.

Dr Tom Hills is a Clinical Immunologist and Infectious Diseases Physician at Te Toka Tumai Auckland Hospital and the Infectious Diseases Programme Lead at the Medical Research Institute of New Zealand. His main areas of interest are the management of infections in critically ill patients and in people with compromised immunity. His research focuses on the design of adaptive platform trials to efficiently identify effective treatments for patients with severe infections.

Sheila Myatra is a Professor of Critical Care Medicine, working at the Tata Memorial Hospital in Mumbai, India. She is the immediate Past President of the Indian Society of Critical Care Medicine. She is the Chair of the Intensive & Critical Care Medicine Committee of the World Federation of Societies of Anaesthesiologists. She is the Past President of the All India Difficult Airway Association.

She is a member of the Surviving Sepsis Campaign Research Committee, COVID Guidelines Committee and the SSC 2025 Guideline Committee. She is the Steering Committee Member of the Asia Pacific Sepsis Alliance. She is among the 14 international airway experts on the American Society of Anesthesiologists difficult airway guidelines and the PUMA guidelines (Project for the Universal Management of the Airway). She has led the first Guideline for tracheal intubation in ICU (IJA 2016). She led the COVID Steroid 2 trial (JAMA Nov.2021) and the INTUBE Study (JAMA Mar. 2021) in India (second author on both papers). Her research interests include hemodynamic monitoring, airway management and sepsis. She has developed a new test in hemodynamic monitoring, called the “tidal volume challenge” (CCM 2017).

Prof Myatra delivered the William C Shoemaker Honorary Lecture at SCCM 2023 in San Francisco, USA. She was awarded the prestigious 2023 ESICM Honorary Membership at ESICM Lives in Milan and the European Airway Management Society (EAMS) Honorary Membership in 2022. She was awarded FCCM in 2015 (American College of CCM) and FICCM in 2013 by ISCCM. She serves on the Editorial Board of several journals.

Twitter: @SheilaMyatra

Cathy McKenzie is a Consultant Pharmacist and Honorary Associate Professor in the Faculty of Medicine, University of Southampton. She has extensive knowledge and clinical experience of pharmacokinetics, pharmacodynamics, and drug use in critical illness.

Her research interests are pharmacokinetics and pharmacological interventions in sedation, opioids and delirium in the intensive care unit. She has published extensively in these fields and in ICU pharmacy practice. Cathy has led and collaborated in many research projects in ICU. She is currently funded via a Southampton Research Leaders Fellowship.

Cathy is also editor in chief for Critical Illness (www.medicinescomplete.com), an e-book
published by Pharmaceutical Press.

Twitter:  @cathymac40

Prof Anthony Gordon is the Chair in Anaesthesia and Critical Care at Imperial College London, an NIHR Senior Investigator (previously NIHR Research Professor) and works as an Intensive Care consultant at St Mary’s Hospital. His research focuses on developing precision medicine in sepsis.

He leads a multidisciplinary group investigating the use of -omic techniques and artificial intelligence (AI) to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies. He has led multiple clinical trials that have shaped international sepsis guidelines. He is the UK Chief Investigator for the international REMAP-CAP trial for COVID-19 and influenza, that has generated evidence that has improved treatments for and saved
hundreds of thousands of lives from severe COVID-19 around the world. He has recently been appointed as the Director of the NIHR/NHS National Research Collaboration Programme (NRCP).

Twitter:  @agordonICU

Dr. Leticia Kawano-Dourado MD PhD is a researcher affiliated with the Hcor Research Institute, Hcor Hospital, Sao Paulo, and at the Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Brazil. Hcor stands as a pioneering institution in South America in the area of Critical Care Medicine, driving numerous important clinical trials.

In recent years, Dr. Kawano-Dourado has delved into adaptive designs notably through her involvement in the RENOVATE trial, for which she is the chief investigator, and REMAP-ILD. RENOVATE is an adaptive trial designed in collaboration with Berry Consultants, and REMAP-ILD, a perennial adaptive platform trial inspired by REMAP-CAP also designed in collaboration with Berry consultants.

Amidst the COVID-19 crisis, Dr. Kawano-Dourado redirected her focus towards COVID-19 research, conducting research and co-authoring publications with the Hcor research team on topics including drug repurposing, and respiratory support in COVID-19. She also served as clinical chair of the WHO Living Guidelines on Drug Treatments for COVID-19. Because of COVID-19, she ventured into the realm of meta-epidemiology research through guideline development, continuing her work with MAGIC Evidence Ecosystem Foundation, Oslo, Norway. Beyond her scientific contributions, Dr. Kawano-Dourado is a passionate advocate for more gender equity in science and medicine, championing inclusivity and diversity in her field.

Twitter: @leticiakawano | LinkedIn: Leticia Kawano-Dourado

Lennie is an ICU consultant with a background in infectious diseases and epidemiology. She obtained her Ph.D. after successfully defending her thesis "Controlling antibiotic resistance in the ICU" in 2013. Her research focuses on innovative trial design, mainly in sepsis and severe infections. She is the immediate past chair of the International Trial Steering Committee of REMAP-CAP, an Adaptive Platform Trial investigating the best treatment for pneumonia, including Covid-19. Lennie is a co-applicant and work package leader on EU-funded projects RECOVER and ECRAID-Base, and co-applicant on several international collaborative grants.

Twitter:  @Lennie333

Kirsten Bibbins-Domingo, PhD, MD, MAS is 17th Editor-in-Chief of the Journal for the American Medical Association. She is the Lee Goldman, MD Professor of Medicine and Professor of Epidemiology and Biostatistics at the University of California, San Francisco. She previously served as the Chair of the Department of Epidemiology and Biostatistics and as the inaugural Vice Dean for Population Health and Health Equity in the UCSF School of Medicine. She co-founded the UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital that focuses on actionable research to improve health equity and reduce health disparities.

Dr. Bibbins-Domingo is a general internist and cardiovascular epidemiologist whose scholarship includes observational epidemiology, pragmatic trials, and simulation modeling to examine clinical and public health approaches to prevention in the US and globally. She previously served on and led the US Preventive Services Task Force from 2010-2017. She has received numerous honors, including induction into the American Society for Clinical Investigation, the National Academy of Medicine, and the American Academy of Arts and Sciences.

Twitter:  @KBibbinsDomingo

Darren Taichman, MD, PhD, MACP is a pulmonary and critical care physician who practices and teaches at the University of Pennsylvania.  At Penn, he was Director of the intensive care unit and led research programs focused on critical care medicine and pulmonary vascular disease.  Dr. Taichman’s editorial work began in 2007 at the Annals of Internal Medicine, where he was the Executive Editor as well as Vice President of the American College of Physicians, the largest medical specialty organization in the United States.  He served as Secretary of the International Committee of Medical Journal Editors from 2014 – 2021.  In 2020, Dr. Taichman was appointed Deputy Editor and Online Editor of the New England Journal of Medicine, as well as the Executive Strategy Editor for the NEJM Group.  He continues to teach and see patients at the University of Pennsylvania, with a specific focus on the treatment of pulmonary hypertension.